Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.62)
# 1,939
Out of 5,245 analysts
53
Total ratings
38.3%
Success rate
7.17%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STTK Shattuck Labs | Initiates: Overweight | n/a | $6.10 | - | 1 | Apr 27, 2026 | |
| MANE Veradermics | Initiates: Overweight | n/a | $101.62 | - | 1 | Mar 2, 2026 | |
| EVMN Evommune | Initiates: Overweight | n/a | $22.87 | - | 1 | Dec 1, 2025 | |
| MDGL Madrigal Pharmaceuticals | Upgrades: Overweight | n/a | $517.26 | - | 5 | Nov 5, 2025 | |
| ATYR aTyr Pharma | Downgrades: Neutral | n/a | $0.49 | - | 2 | Sep 15, 2025 | |
| AVTX Avalo Therapeutics | Initiates: Overweight | n/a | $16.35 | - | 1 | Aug 15, 2025 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $39.19 | +65.86% | 13 | Jun 23, 2025 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $8.32 | - | 7 | May 6, 2025 | |
| TVTX Travere Therapeutics | Reiterates: Overweight | n/a | $44.43 | - | 3 | Apr 23, 2025 | |
| ACRS Aclaris Therapeutics | Reiterates: Overweight | n/a | $4.52 | - | 1 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.19 | - | 3 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.26 | +206.75% | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $18.19 | - | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $24 | $38.87 | -38.26% | 2 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $450 | $2.42 | +18,495.04% | 1 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $2.26 | +519.47% | 1 | Mar 3, 2021 |
Shattuck Labs
Apr 27, 2026
Initiates: Overweight
Price Target: n/a
Current: $6.10
Upside: -
Veradermics
Mar 2, 2026
Initiates: Overweight
Price Target: n/a
Current: $101.62
Upside: -
Evommune
Dec 1, 2025
Initiates: Overweight
Price Target: n/a
Current: $22.87
Upside: -
Madrigal Pharmaceuticals
Nov 5, 2025
Upgrades: Overweight
Price Target: n/a
Current: $517.26
Upside: -
aTyr Pharma
Sep 15, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.49
Upside: -
Avalo Therapeutics
Aug 15, 2025
Initiates: Overweight
Price Target: n/a
Current: $16.35
Upside: -
Structure Therapeutics
Jun 23, 2025
Reiterates: Overweight
Price Target: $65
Current: $39.19
Upside: +65.86%
ORIC Pharmaceuticals
May 6, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.32
Upside: -
Travere Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $44.43
Upside: -
Aclaris Therapeutics
Mar 18, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.52
Upside: -
Jan 21, 2025
Downgrades: Neutral
Price Target: n/a
Current: $11.19
Upside: -
Dec 17, 2024
Initiates: Overweight
Price Target: $10
Current: $3.26
Upside: +206.75%
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $18.19
Upside: -
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $38.87
Upside: -38.26%
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.42
Upside: +18,495.04%
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $2.26
Upside: +519.47%